Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PsilOCD
NCT06258031Phase 1Completed
- Sponsor
- Imperial College London
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of psilocybin in obsessive compulsive disorder (OCD), sponsored by Imperial College London. Primary endpoints: Intradimensional-extradimensional set shift at 4 weeks and Visual long-term potentiation electroencephalogram paradigm at 8 weeks. Started Oct 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT06258031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258031.